Needle-free intranasal Covid-19 vaccine gets green-light for trials 

Oragenics has entered into an agreement with KBI Biopharma for the process transfer, process optimisation and cGMP manufacturing of the company’s intranasal vaccine candidate NT-CoV2-1, which is expressed in a proprietary CHO cell line.  

Background 

Oragenics previously demonstrated robust immune response and reduction of SARS-CoV-2 viral loads to undetectable levels in the nasal passages and lungs five days following a viral challenge in preclinical models. The company intends to file an IND in 2022 to conduct a first-in-human clinical study with NT-CoV2-1. 

Official comments  

“We are delighted to enter into a development collaboration for our SARS-CoV-2 intranasal vaccine candidate with an outstanding commercial partner. Successful completion of work under this agreement will enable Oragenics to secure material for a future expected Phase II clinical trial. Intranasally delivered SARS-CoV-2 vaccines could provide increased protection in the nose and throat where viral entry occurs. This could lead to lower transmission of the virus compared to the currently available intramuscularly delivered vaccines as well as offering a needle-free delivery option,” said Frederick Telling, Ph.D., Executive Chairman of Oragenics. 

“As a contract manufacturer accelerating the development of innovative discoveries into life-changing biological products, KBI is perfectly positioned for first manufacturing for Oragenics,” said Brandon Vail, Senior Vice President of KBI Business Development. “KBI is proud of the important role in the continued fight against SARS-CoV-2 through our partnership with Oragenics.” 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free